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The ability of p53 to regulate transcription is crucial
for tumor suppression and implies that inherited
polymorphisms in functional p53-binding sites could
influence cancer. Here, we identify a polymorphic
p53 responsive element and demonstrate its influ-
ence on cancer risk using genome-wide data sets
of cancer susceptibility loci, genetic variation, p53
occupancy, and p53-binding sites.We uncover a sin-
gle-nucleotide polymorphism (SNP) in a functional
p53-binding site and establish its influence on the
ability of p53 to bind to and regulate transcription
of the KITLG gene. The SNP resides in KITLG and
associates with one of the largest risks identified
among cancer genome-wide association studies.
We establish that the SNP has undergone positive
selection throughout evolution, signifying a selective
benefit, but go on to show that similar SNPs are rare
in the genome due to negative selection, indicating
that polymorphisms in p53-binding sites are primar-
ily detrimental to humans.
INTRODUCTION
Common inherited genetic factors have great potential to help us
better understand the origins, progression, and treatment of hu-
man cancer and to serve as important biomarkers in the clinic to
identify those at increased risk for developing cancer, progress-
ingmore rapidly, and not responding to therapies. Genome-wide410 Cell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc.association studies (GWASs) have identified almost 900 single-
nucleotide polymorphisms (SNPs) significantly associated with
cancer susceptibility traits. However, discerning the causal
SNPs responsible for the associations from the nonfunctional
associated SNPs has proven challenging. Interestingly, many
cancer-associated SNPs identified in GWASs are significantly
enriched in noncoding functional DNA elements as defined by
the ENCODE project (ENCODE Project Consortium et al.,
2012). Indeed, single locus and gene-specific studies have pre-
sented strong data to support the role of polymorphic transcrip-
tional regulatory elements in influencing the risk of cancers of the
breast, kidney, colon, and connective tissues (Bond et al., 2004;
Post et al., 2010; Scho¨del et al., 2012; Sur et al., 2012).
One of the most important and well-studied transcription fac-
tors in cancer is the p53 tumor suppressor. Three decades of
intense study have clearly demonstrated that p53 is a central
node of a cellular stress response pathway that is crucial in sup-
pressing cancer formation in many tissue and cell types (Lane
and Levine, 2010) and in regulating other processes such as
pigmentation, fecundity, cellular metabolism, mitochondrial
respiration, stem cell maintenance, and early embryonic devel-
opment (Belyi et al., 2010; Junttila and Evan, 2009; Lu et al.,
2009). Upon cellular stresses such as DNA damage, replicative
stress, oncogene activation, hypoxia, and translational stress,
p53 is activated and initiates cellular responses such as DNA
repair, cell-cycle arrest, apoptosis, and senescence. p53 deter-
mines these cellular fates primarily through its ability to regulate
the transcription of numerous target genes through direct,
sequence-specific, DNA binding (Bieging and Attardi, 2012; Ni-
kulenkov et al., 2012; Sperka et al., 2012). Indeed, with the
advent of technologies that can screen for genome-wide p53
occupancy, coupledwith the ability tomeasure the relative levels
of almost all known transcripts, many more important p53 target
genes are currently being defined (Bandele et al., 2011; Botch-
eva et al., 2011; Nikulenkov et al., 2012; Smeenk et al., 2011;
Wei et al., 2006).
In order to regulate the vast majority of p53-target genes, p53
directly binds a DNA consensus site via its centrally located
sequence-specific DNA-binding domain (DBD). Under most
conditions, it binds the consensus site as a homotetramer and,
once bound, recruits transcriptional coactivators to regulate
transcription via an N-terminal transactivation domain (Becker-
man and Prives, 2010). Its DNA consensus motif, the p53
response element (p53-RE) is composed of two decameric
half-sites, RRRCWWGYYY (where W = A or T, R = purine and
Y = pyrimidine), separated by a spacer of 0–13 nucleotides,
and indeed a recent study suggests that p53 prefers p53-REs
with half-sites separated by 0–2 nucleotides (Jolma et al.,
2013). p53’s ability to bind the p53-RE and subsequently regu-
late transcription is crucial for its tumor suppressor function
(Chao et al., 2000; Crook et al., 1994; Pietenpol et al., 1994). A
reflection of this lies in the fact that approximately 50% of human
cancers carry somatic mutations of the p53 gene over 80% of
which are missense mutations spanning the highly conserved
DBD (Freed-Pastor and Prives, 2012). Moreover, many of the
same somatic DBD mutations can be found as inherited,
cancer-causing mutations in extremely cancer-prone families
belonging to the Li-Fraumeni syndrome (Malkin et al., 1990).
Together, these observations suggest the possibility that
SNPs in key bases of functional p53-REs (p53-RE SNPs) could
influence the ability of p53 to regulate transcription and result
in differences in cancer susceptibility (Bandele et al., 2011; Nour-
eddine et al., 2009). In this report, we identify and describe a SNP
in a functional p53-RE that affects the ability of p53 to regulate
transcription and influence cancer susceptibility and has under-
gone positive natural selection throughout human evolution.
However, we go on to determine that SNPs in similar functional
p53-REs genome-wide have been subjected to negative selec-
tion. Our data indicate that polymorphisms in functional p53
response elements are primarily detrimental but in rare instances
can impart selective benefits, rising to substantial frequencies in
populations and resulting in differences in cancer susceptibility
among individuals.
RESULTS
One of the Strongest Cancer GWAS SNPs Resides in a
Key Position of a Functional p53 Response Element
We reasoned that if SNPs in key nucleotides of functional p53-
REs can lead to differential cancer risk, then at least one cancer
GWASSNP or proxy (a SNP in linkage disequilibrium [LD]) should
reside in a genomic region occupied by p53, containing a strong
p53-RE and in a key nucleotide of the element. To explore this
possibility, we determined that the 892 SNPs known to
be associated with cancer in GWAS (p values below 1 3
105;www.genome.gov/gwastudies, www.ncbi.nlm.nih.gov/
sites/entrez?db=gap, www.hugenavigator.net/CancerGEMKB/
caIntegratorStartPage.do) were in strong LD with 61,675 other
SNPs in the genome (r2 R 0.8). To assess which of these
62,567 cancer GWAS SNPs reside in p53-occupied genomic re-gions, we integrated p53 chromatin immunoprecipitation
sequencing (ChIP-seq) data derived from four different labora-
tories (Bandele et al., 2011; Nikulenkov et al., 2012; Botcheva
et al., 2011; Smeenk et al., 2011) utilizing six different cell lines
derived from four different tissues: MCF7 (breast cancer),
IMR90 (fibroblasts), U2OS (osteosarcoma), and lymphoblastoid
cell lines (LCL; GM06993, GM11992, and GM12878). Cells
were treated with seven different p53-activating agents (5-fluo-
rouracil, Nutlin-3, RITA, actinomycin-D, etoposide, doxorubicin,
and ionizing radiation), resulting in p53 ChIP-seq peaks from 11
different combinations of cell lines and treatments (Table S1).
Utilizing the same peak calling algorithm (QuEST; Valouev
et al., 2008) for all four independent studies, we noted a total
of 20,838 significant peaks (stringent peak calling parameters,
FDR q = 0.05), of which 17,118 are unique peaks (Figure 1A).
With this data, we were able to determine that 86 of the 62,567
cancer GWAS SNPs reside in genomic regions occupied by
p53 in at least one experiment (Figure 1B and Table S2).
To evaluate which of the 86 cancer GWAS SNPs also reside in
a strong p53-RE, we used position weight matrix (PWM) calcula-
tions computed from 228 published p53-REs to analyze the
sequences surrounding these SNPs (Table S3). As seen in Fig-
ure 1C, the 228 published p53-REs have a mean PWM score
of 13.8 (median of 14) ranging from 5.1 to 21.7, with sequences
scored greater than the mean having strong similarity with the
canonical p53-RE. Interestingly, only one of the 86 SNPs resides
in a key nucleotide of a p53-RE with an above average PWM
(rs4590952, G/A, PMW = 15.6/11.1). As predicted by the high
PMW score, an almost canonical p53-RE is found in this region
(Figure 2A). However, the PWM score decreases dramatically
with the A allele because it disrupts the G nucleotide in the
core CWWGmotif of the second decamer (PWM11.1, difference
of 4.5). The SNP, KITLG p53-RE SNP, rs4590952 (G/A), is in LD
with rs995030, rs3782181, and rs4474514 (Figure 2B), which
have been shown in three GWASs (Kanetsky et al., 2009; Rapley
et al., 2009; Turnbull et al., 2010) to associate with differential risk
for developing testicular cancer in Caucasians with a per allele
odds ratio (OR) of up to 3.07 (p = 1.03 1031, Table S4). Interest-
ingly, this is one of the highest and most statistically significant
ORs noted to date in GWASs (Chanock, 2009).
The KITLG p53-RE SNP Displays Signatures of Recent
Positive Selection
A number of previously defined, functional p53 pathway SNPs
display characteristic global allele frequencies and haplotype
structures that suggest certain alleles have undergone selective
sweeps throughout evolution (Atwal et al., 2007; Atwal et al.,
2009; Beckman et al., 1994; Shi et al., 2009). These findings are
consistent with the roles of this pathway in many processes sub-
ject to selective pressures, such as pigmentation, fecundity, and
early embryonic development. Therefore, we next explored the
possibility that the KITLG p53-RE SNP has also been subjected
to natural selection pressures. Interestingly, the KITLG p53-RE
SNP harbors two different signatures of recent natural selection
in humans. First, in Caucasian Europeans, the frequency of the
G allele with the stronger predicted p53-RE is 80%, in contrast
to only 24% in Africans (Figure 2C, 1000 Genomes Project).
This dramatic allele-frequency difference is significantly greaterCell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc. 411
Figure 1. A Cancer GWAS SNP Resides in a
Key Position of a Functional p53 Response
Element
(A) A Venn diagram of all p53-occupied genomic
regions from the four different studies incorpo-
rated in the genomic scan.
(B) A Circos plot displaying the cancer GWAS
SNPs and their proxies screened for the presence
of p53 occupancy, an above average p53-RE and
location in a core nucleotide of the RE. Chromo-
somes are arranged in a half-circle end-to-end
with chromosome’s cytobands in the outer ring.
The location of the 892 cancer GWAS SNPs are
displayed in the green inner ring and their 61,675
proxies are displayed in the blue ring. Grey lines
identify those SNPs that are occupied by p53 in
at least in one condition studied. Orange lines
identify the two occupied polymorphic regions
with above average p53-REs. The red line iden-
tifies the SNP that also resides in a core nucleotide
of the RE.
(C) A histogram of the position weight matrix
(PWM) scores of the 228 known p53-binding sites
(p53-REs) that were utilized to calculate the ma-
trix, which was incorporated in the genomic scan.
Also shown are examples of below average,
average, and above average p53-REs, as well as
the well-described consensus p53-RE. See also
Tables S1, S2, and S3.than would be expected by genetic drift alone, as indicated by a
fixation index (F-st) of 0.301 (Amigo et al., 2008). Similarly, in
Europeans, the haplotype(s) associated with the G allele are
significantly longer and present with a higher degree of homozy-
gosity, as indicatedbyan integratedHaplotypeScore (iHS) of 2.3,
which is among the strongest 5% of all signals of positive selec-
tion in the genome (Figure 2D) (Gautier and Vitalis, 2012) and is
similar to previously reported observations (Lao et al., 2007).
Together, these two signatures of natural selection provide evi-
dence that the G allele with the stronger predicted p53-RE has
undergone a selective sweep in Caucasians in a similar manner
to previously defined, functional p53 pathway SNPs.
KITLG Is a Common p53 Target Gene that Can Increase
Cellular Proliferation
The transcriptional activation of KITLG upon p53 activation has
been clearly demonstrated in multiple studies utilizing different412 Cell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc.cell types, different p53-activating stimuli
and different measurement techniques
(McGowan et al., 2008; Murase et al.,
2009; Smeenk et al., 2011; Terzian
et al., 2010; Wei et al., 2006). Consistent
with this, we observed significant p53
binding to KITLG in the region that har-
bors the KITLG p53-RE SNP, in 10 out
of 11 different cell line and treatment
combinations (Figure 3A). This observa-
tion not only provides overwhelming evi-
dence for an in vivo association of p53
with the KITLG p53-RE, but also placesit in a class of p53-REs that are bound by p53 when activated
by many different mechanisms; the so-called ‘‘default’’ p53-
REs (Table S5) (Bandele et al., 2011; Nikulenkov et al., 2012;
Wei et al., 2006). Indeed, in Figure S1 (available online), we pre-
sent the significant fold activation of KITLG in six diverse cell
types compared to the induction of one of the most well-studied
default p53 target genes CDKN1A (p21). The cells we studied
were derived from germ cell, testicular, leukemia, and renal can-
cers, as well as primary human keratinocytes and Sertoli cells.
Specifically, we measured KITLG and p21 levels using qRT-
PCR before and after p53 activation by Nutlin-3, one of the
most specific p53 activators. Importantly, we found a significant
fold-induction of KITLG in all cells tested. Specifically, after p53
activation, we noted an average 6.8-fold induction of KITLG,
ranging from 1.7-fold to 16-fold. These values were strikingly
similar to the induction of p21 with an average fold induction of
5.17, ranging from 2.6-fold to 8.8-fold. Together with the results
Figure 2. The KITLG p53-RE SNP,
rs4590952 (G/A) Is Closely Linked to One of
the Strongest Cancer GWAS SNPs and
Harbors Two Signatures of Recent Natural
Selection
(A) Sequence of the p53-RE in which rs4590952
resides. Nonconsensus bases are shown in gray
and the spacer nucleotide is in black. Core bases
are underlined in blue.
(B) A linkage disequilibrium (LD) analysis (r2 values)
of the KITLG p53-RE SNP, rs4590952 (boxed in
red), with the three SNPs that have been identified
in three independent GWASs to associate with
differential risk for developing testicular cancer in
Caucasians.
(C) Pie charts of the allele frequencies of theKITLG
p53-RE SNP in the African (AFR) and European
(EUR) individuals from the 1000 Genomes Project.
Also noted is the fixation index (F-st).
(D) A plot of the absolute values of the standard-
ized integrated haplotype scores (iHS) for SNPs
spanning the KITLG gene indicating significant
allelic differences in haplotype structure indicative
of positive selection. The red line denotes the
location of rs4590952 (marked in red) and the
yellow coloring denotes the SNPs known to be in
strong LD with rs4590952. Below is a schematic
depiction of the KITLG gene with exons and in-
trons noted, as well as the genetic variations in the
gene, together with an LD analysis (r2). The red
color denotes variations with high r2 values. See
also Table S4.from our genomic analysis and the previously published obser-
vations, these data suggest that KITLG expression can be regu-
lated utilizing the p53-RE in a p53-dependent manner in many
cell types and under many activating stimuli.
Because the KITLG p53-RE SNP is associated with differential
cancer risk, and the action of p53 on the KITLG locus is so strik-
ingly preserved in different cell types and upon different acti-
vating stimuli, we reasoned that the p53-dependent regulation
of KITLG signaling could have a profound effect on an important
hallmark of cancer such as cellular proliferation. To test this, we
chose to examine the impact of p53-dependentKITLG activation
on the developing pigmentary system inmice, wheremany of the
initial roles of KIT pathway signaling were first described. Specif-
ically, KITLG and its receptor C-KIT are a part of a pathway that isCell 155, 410–422,known to be central in regulating prolifer-
ation, survival and migration of primordial
germ cells, melanoblasts and hematopoi-
etic stem cells (Lennartsson and Ro¨nn-
strand, 2012). In the pigmentary system,
ultraviolet radiation induces p53-Kitlg
signaling in keratinocytes, which in turn
affects melanocytes that express the
c-Kit receptor in order to mount a cuta-
neousUV response such as tanning (Mur-
ase et al., 2009). Interestingly, when we
compared this response in mice either
wild-type (WT) or null for p53 (p53 null),we noted dramatic differences. First, we irradiated WT pups at
postnatal day 2 (P2) with a melanoma-inducing 5.6 kJ/m2 of
ultraviolet (UV) light (Walker et al., 2009) and observed an up to
16-fold increase in epidermal melanocyte numbers after UVR
compared to nontreated mice (Figure S2A). In parallel, we exam-
ined Kitlg expression in nonirradiated WT and p53 nullmice and
observed that Kitlg was induced 2.15-fold between birth (post-
natal day 0 [P0]) and P3 in WT mice; however, in p53 null mice
it was not induced (Figure S2B). When we irradiated WT and
p53 null P2 pups, we noted that melanocyte numbers were
increased up to 4.6-fold that observed in p53 null mice (Fig-
ure S2C), and melanocyte proliferation was increased almost
3-fold in WT versus p53 nullmice (Figure 3B). Concurrently, Kitlg
expression was induced 2.5-fold in WT skin but was not inducedOctober 10, 2013 ª2013 Elsevier Inc. 413
Figure 3. The KITLG p53-RE SNP Resides in a p53 Target Gene that Can Increase Cellular Proliferation and Is Frequently Occupied by p53 in
an Allele-Specific Manner
(A) Genome browser tracks depicting the read density at rs4590952 for 10 of the 11 p53 ChIP-seqs included in this study as visualized using Quest. GWAS SNPs
and rs4590952 are displayed.
(B) TRP1 and Ki67 double staining to identify proliferating melanocytes (MCs) in the epidermis. WT and p53/mice were irradiated at P2 with 5.6 kJ/m2 UV and
the percentage of epidermal MCs determined in a minimum of three mice of each genotype at 3–5 days after treatment. (*Mann-Whitney U-test p < 0.05).
(C) Kitlg gene expression differences (± SEM) in WT and p53/mice 24 hr after UV exposure (P3) expressed as fold change and referenced to the nontreated P3
expression level for the respective genotype. A minimum of five pups were used for expression estimates at each time point. (#Mann-Whitney U-test p = 0.002).
(D) Visualization of the 57 unique, individual reads containing the polymorphic A/G nucleotide in theKITLG p53-RE. (E) A bar graph depicting the allelic differences
in the relative amounts (± SEM) of p53-immunoprecipitated DNA compared to the input DNA for three different LCL cell lines heterozygous for the KITLG p53-RE
SNP. See also Figures S1 and S2, as well as Table S5.in p53 nullmice (Figure 3C). These data provide strong evidence
that in its natural setting, the action of p53-Kitlg signaling results
in a measurable effect on a cancer-related process such as
cellular proliferation.
TheKITLG p53-RE SNP Is Frequently Occupied by p53 in
an Allele-Specific Manner
To explore the prediction that p53 could occupy the KITLG p53-
RE in an allele-specific manner, we examined the sequence
reads generated from the p53 ChIP-seqs in greater detail.
From the reads, we determined that three of the four cell types
were homozygous for the G allele. One of the studies incorpo-
rated heterozygous cell lines, two HapMap CEU LCL414 Cell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc.(GM06993 and GM11992), which were treated with doxorubicin
(Bandele et al., 2011). In support of the hypothesis that the G
allele creates a stronger p53-RE, of the 57 unique sequencing
reads precipitated with p53 antibodies, 65% contained the G
allele (37) and 35% the A allele (Figure 3D, p = 0.033, binomial
test). In order to further investigate allelic differences in p53 bind-
ing, we used a RT-PCR allele discrimination assay for the KITLG
SNP to quantify alleles in p53-immunoprecipitated DNA
compared to input DNA in three heterozygous LCL cell lines:
GM11992, GM11831, and GM12815. Notably, for each LCL,
the G allele with the stronger p53-RE was detected at a
higher level in the p53-immunoprecipitated DNA compared
to A allele sequences (Figure 3E) (GM11992 = 2.8-fold
Figure 4. The KITLG p53-RE SNP Results in
Allele-Specific Differences in p53-Depen-
dent Transactivation
(A) The 60 base pair region surrounding the SNP,
which was cloned into a pGL3 luciferase reporter
vector.
(B) A bar graph depicting the fold ratio of luciferase
activity from transiently transfected reporter
plasmids containing either the G or A alleles into a
pair of HCT116 cell lines containing either the wild-
type p53 gene (+/+) or without (/).
(C) A bar graph depicting the fold ratio of luciferase
activity from the reporter plasmids into seven
diverse cancer cell lines with wild-type p53,
mutant, or no p53.
(D) A bar graph depicting the fold ratio of luciferase
activity in the cell lines with mutant or no p53 upon
cotransfection with an expression vector con-
taining wild-type p53 cDNA, as well as a western
blot analysis of p53 levels in the transfected cell
lysates. Top: western blots using a monoclonal
p53 antibody (DO1). Bottom: western blots of the
same filter using antibodies to either actin or KU-
80 as loading controls. Error bars represent SEM
of three independent experiments each performed
multiple times.G:A; GM11831 = 1.8-fold G:A, and GM12815 = 1.5-fold G:A),
thereby lending further support to themodel that p53 can occupy
the KITLG p53-RE in an allele-specific manner.
The KITLG p53-RE SNP Results in Allele-Specific
Differences in p53-Dependent Transactivation of KITLG
To assess whether the KITLG p53-RE SNP affects p53-depen-
dent transcriptional activation, we cloned a 60 bp region sur-
rounding the SNP for each allele into a pGL3 luciferase reporter
vector (Figure 4A). To test p53 dependence, we transfected each
of these constructs into the colorectal cancer wild-type p53 cell
line (HCT116 p53+/+) and its isogenic p53 null form (HCT116
p53/). Interestingly, 7-fold more luciferase activity wasCell 155, 410–422,measured from the reporter containing
the G allele compared to the A allele in
HCT116 p53+/+ cells (p = 0.003, Mann-
Whitney Test, Figure 4B). In contrast, no
significant differences in luciferase activ-
ity levels between the two variant alleles
could be measured in the HCT116
p53/ cells (Figure 4B). To extend this
study to cells derived from other cancers
and, importantly, to cells derived from
testicular cancers, we transfected the re-
porter plasmids into four p53 wild-type
cell lines (GH, testicular; Tera1, testicular;
Tera2, testicular; and MCF7, breast) and
three p53 mutant or null cell lines (CRL-
2073, germ cell tumor; H1299, lung; and
Soas2, osteosarcoma). In the p53 wild-
type cells we measured, on average,
188-fold more luciferase activity fromthe G-allele-containing reporter than the A allele reporter,
ranging from 93- to 373-fold (Figure 4C). Consistent with the re-
sults obtained in the HCT116 p53/ cells, we measured, on
average, a nonsignificant 1.5-fold increase in luciferase activity
from the G allele reporter relative to the A allele when tested in
the three p53 mutant or null cell lines, ranging from 1.1 to 2.1.
In order to further confirm the p53-dependence of these effects,
we attempted to rescue the lack of significant fold difference in
reporter expression in these three p53 mutant/null cell lines. To
do this, we cotransfected an expression vector (pcDNA3) con-
taining wild-type p53 cDNA with both reporters. Importantly,
we were able to restore wild-type p53 expression in all three
cell lines and to note an average 13-fold increase in luciferaseOctober 10, 2013 ª2013 Elsevier Inc. 415
Figure 5. The KITLG p53-RE Demonstrates
Allele Specific Enhancer Activity when Pre-
sent at Single Copy in Murine ES Cells in
an Hsp68-LacZ Enhancer Trap Assay
(A) Top: the 452 bp region surrounding the SNP,
cloned from either the A or the G allele, inserted
into an Hsp68-LacZ enhancer trap vector con-
tained within a PhiC31 integrase attB flanked
cassette exchange vector. Center: the PhiC31 in-
tegrase attP flanked docking site within the
ROSA26 locus. PhiC31 integrase catalyzes the
recombination between the attB sites on the ex-
change vector and the attP sites positioned within
the ROSA26 locus, leading to the targeted inte-
gration of the enhancer trap construct. Bottom:
the conformation of the three alleles that were
used in the study.
(B) X-gal staining of ES cells harboring either the
empty Hsp68-LacZ cassette (control reporter) or
the KITLG p53-RE enhancer-Hsp68-LacZ cas-
settes (A allele reporter and G allele reporter).
(C) A box plot depicting the difference in the beta-
galactosidase activity of the targeted ES cells
harboring the three different constructs. Whiskers
in the box plot graph represent minimum and
maximum values.activity from the G allele reporter over the A allele reporter,
ranging from 3-fold to 30-fold (Figure 4D), thus rescuing the G-
allele-dependent increase in transcription.
To formally assign enhancer activity to the polymorphic KITLG
p53-RE region when present within the genome, an enhancer
trap assay was performed using the Hsp68-LacZ reporter sys-
tem in murine embryonic stem (ES) cells (Kothary et al., 1988).
To facilitate the comparison between the empty control and
the putative enhancer containing vectors, the test vectors were
targeted to the ROSA26 locus via PhiC31 integrase-mediated416 Cell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc.cassette exchange (Chen et al., 2011)
(Figure 5A). ES cell clones harboring the
basal Hsp68 promoter alone resulted in
only minimal beta-galactosidase expres-
sion, whereas ES cells harboring the
identically positioned construct together
with a 452 bp region surrounding the
KITLG p53-RE region yielded robust
beta-galactosidase expression, thus
proving the region to have significant
enhancer activity (p = 0.001 Kruskal-
Wallis test) (Figures 5B and 5C). Further-
more, ES cells harboring the G allele
enhancer yielded a significant 1.9-fold in-
crease in beta-galactosidase activity
over ES cells harboring the A allele (p =
0.011 Mann-Whitney test). These results
demonstrate that even at a single
genomic copy, the p53-RE SNP region
is able to confer enhancer activity, with
the G allele conferring significantly higher
expression than the A allele.To test this further in the context of the endogenous gene, we
measured the allele-specific levels of KITLG mRNA in heterozy-
gous cells with wild-type and mutant p53. First, we identified
only one heterozygous, p53 wild-type cell line from the above-
mentioned four testicular cancer cells, namely GH. Therefore,
in order to obtain additional heterozygous cell lines, we geno-
typed the NCI60 cell panel (Table S6). Fourteen of the 59 cell
lines contain wild-type p53 (http://p53.free.fr/index.html), and
genotyping for the KITLG-SNP identified two cell lines to be het-
erozygous: SR (acute lymphoblastic leukemia) and UO-31 (renal
Figure 6. KITLGDemonstrates Allelic Imbalance in Transcript Levels
in a p53-Dependent Manner
(A) A LD regional plot depicting the 200 kb surrounding theKITLG p53-RESNP.
The diamonds represent the SNPs in the region, with the orange diamonds
highlighting the SNPs in high LD with the KITLG p53-RE SNP (r2 > 0.8). The
green diamonds denote the KITLG p53-RE SNP (rs4590952) and the 30UTR
SNP rs1061981. The KITLG gene is denoted by the green arrow. The plot was
generated with 1000 Genomes Project data using the online tool SNAP from
the Broad Institute at MIT available at: http://www.broadinstitute.org/mpg/
snap/ldsearch.php. Bar graphs depict the differences in the relative tran-
scription of KITLG from each allele of a strongly linked exonic SNP (rs1061981
C/T), whereby the C allele associates with the G allele.
(B) The log fold ratios found in cDNAs compared to genomic DNAs from the
same heterozygous cell line are plotted.
(C) The same measurements were performed for the acute lymphoblastic
leukemia cell line SR, and both alleles were successfully identified in the
genomic DNAs but only the G allele in the cDNA. These data are presented in a
bar graph plotting the cycle threshold values measured for each allele in both
the genomic DNA and the cDNA. For all experiments, error bars represent SEM
of three independent experiments each done in triplicate. See also Table S6.cancer). Forty-five of the cell lines are deficient for p53 activity,
eight of which were determined to be heterozygous. We purified
mRNA from all three logarithmically growing heterozygous cell
lines with wild-type p53 and four heterozygous cell lines deficient
for p53 that were chosen at random (DU145, HOP92, IGROV1,
and MDAMB231). We synthesized cDNA and utilized a closely
linked exonic SNP (rs1061981C/T, Figure 6A) to measure the
allele-specific transcript levels, whereby the C allele associates
with the G allele. Consistent with the previous outcomes, in all
three cell lines with wild-type p53, a significant increase in the
G allele to A allele ratio was noted in the cDNAs compared to
the genomic DNAs. Specifically, 21.7-fold more G-allele-con-
taining transcripts were measured in the testicular cancer cells
GH, and 2.6-fold more in the renal cancer cells UO-31 (Fig-
ure 6B). In the SR cell line, both alleles were successfully identi-
fied in the genomic DNAs but interestingly only the G allele in the
cDNA (Figure 6C). Consistent with the p53-dependence of these
observations, no significant increase in the G allele to A allele ra-
tio was noted in the cDNAs derived from the four p53 mutant
cells (Figure 6B).
The KITLG p53-RE SNP Is Unique in the Genome and
Influences Cancer Susceptibility
Thus far, our genomic analyses and subsequent experimental
validation have supported the assertion that a functional SNP
in a functional p53-RE in the KITLG gene resides among the
62,567 cancer GWAS SNPs. To assess the likelihood that the
KITLG p53-RE SNP’s association with the pool of cancer
GWAS SNPs was by chance, we determined the frequency of
similar SNPs in the genome (Figure 7A). To date, there are known
to be 10,815,471 SNPs in the genome, with a minor allele fre-
quency > 0.05% in the 1000 Genomes Project (Abecasis et al.,
2012). Among these, we determined 3,123 SNPs to reside in
p53-REs with PWM scores greater than or equal to the KITLG
p53-RE (15.5). Of these, only six SNPs are in p53-REs that, like
the KITLG p53-RE, are occupied by p53 after all seven different
p53-activating treatments. Among the six frequently occupied
p53-REs with SNPs, only the KITLG p53-RE SNP resides in a
core nucleotide of the consensus sequence and is predicted to
strongly affect p53 binding (allelic difference of PWM scores >
4.4). Therefore, among the 10,815,471 SNPs throughout the
genome, only one SNP resides in a core nucleotide of a
frequently occupied, strong p53-RE. The likelihood of this p53-
RE SNP being found among the 62,567 cancer GWASs SNPs
by chance is extremely low (p = 0.0058, Fisher’s Exact test, Fig-
ure 7B), lending strong support for a direct influence of theKITLG
p53-RE SNP on cancer susceptibility.
SNPs in Functional p53-REs Are Infrequent in the
Genome Due to Negative Selection
As mentioned above and similar to the KITLG p53-RE SNP, a
number of previously defined, functional p53 pathway SNPs har-
bor alleles that have undergone selective sweeps throughout
evolution. Given this, and the fact that we are only able to identify
a single strongly functional p53-RE SNP among over 10 million
SNPs in the genome, we examined the possibility that functional
p53-RE SNPs are infrequent in the genome, possibly due to
purifying (negative) selection. To do this, we compared theCell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc. 417
Figure 7. The KITLG p53-RE SNP Is Unique
in the Genome and Influences Cancer Sus-
ceptibility
(A) A Circos plot displaying the known 10,815,471
SNPs with minor allele frequencies > 0.05%,
which were screened to determine the number of
SNPs that, like the KITLG p53-RE SNP, reside in a
strong p53-RE, occupied by p53 after all seven
different p53-activating treatments, and in a core
nucleotide of the p53-RE. Chromosomes are ar-
ranged in a half-circle end-to-end with chromo-
some’s cytobands in the outer ring. The locations
of the 10,815,471 SNPs are displayed in the blue
inner ring. The locations of the 3,123 SNPs
residing in strong p53-REs are displayed in the
green inner ring. Orange lines identify those 6
SNPs in p53-REs that are occupied by p53 in after
all at least in seven different p53-activating treat-
ments. The red line identifies the only SNP that
also resides in a core nucleotide of the RE, which is
the KITLG p53-RE SNP.
(B) A graph depicting the genome-wide distribu-
tion of the known 10,815,471 SNPs with minor
allele frequencies > 0.05%, the cancer GWAS
SNPs and their proxies at a 2Mb scale. The num-
ber of SNPs is depicted in a logarithmic scale and
the dotted line denotes the location of the KITLG
p53-RE SNP, rs4590952. The likelihood of this
p53-RE SNP being found among the cancer
GWASs SNPs and proxies by chance is low (p =
0.0058, Fisher’s exact test).
(C) A genome-wide analysis provides evidence of
negative selection of polymorphic p53-REs. The
flowchart depicts the number of 21,904 p53-REs
that are present in the genome in either p53 un-
occupied regions or occupied regions after one
to four or five to seven different p53-activating
treatments. Also displayed is a bar graph repre-
senting the percent values of the p53-REs in each
category that are polymorphic.frequency of p53-occupied polymorphic p53-REs, to the fre-
quency of polymorphic p53-REs never observed to be p53 occu-
pied in the 11 p53 ChIP-seq data sets included in our analysis.
The former are most certainly enriched for functional p53
enhancers, whereas the latter are enriched for nonfunctional
p53-REs. Therefore, if functional p53-REs are under negative
selection pressure to exclude mutations in the consensus site,
we would expect the frequencies of polymorphic p53-REs to
be significantly lower in the p53-occupied REs. To test this, we
identified 21,904 p53-REs genome-wide with a PWM score of
15.5 or greater. Of these, 88% (19,282) were never occupied
by p53. Ten percent (2,091) were occupied by p53 in one to
four different p53-activating treatments, and 2% (531) in five to418 Cell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc.seven treatments (Figure 7C). Interest-
ingly, 15% (2,892/19,282) of the non-
p53-occupied REs contain SNPs. In
contrast, only 9% (194/2,091 in one to
four treatments) and 7% (37/531 in five
to seven treatments) of p53-occupied
REs contain SNPs (Figure 7D). This dra-matic decrease in the frequency of polymorphic p53-REs in the
p53-occupied REs, compared to the nonoccupied REs (up to
2-fold), is highly significant (p < 1 3 1015, Cochran-Armitage
Trend test), and lends support to the hypothesis that polymor-
phisms in functional p53-REs are suppressed in human popula-
tions through negative selection.
DISCUSSION
In this report, we present strong evidence supporting the hypoth-
esis that well-placed polymorphisms in functional p53-binding
sites can result in differential p53-dependent transcriptional
regulation and cancer risk, through the identification and
characterization of the KITLG p53-RE SNP. The KITLG p53-RE
SNP is strongly linked to three SNPs shown, in three indepen-
dent GWASs, to associate with differential risk for developing
seminomatous and nonseminomatous testicular cancer, with a
per allele odds ratio of up to 3.07 (p value = 1.0 3 1031), one
of the highest and most significant findings among all cancer
GWASs (Kanetsky et al., 2009; Rapley et al., 2009; Turnbull
et al., 2010). Based on linkage data, individuals with the G allele,
and therefore the stronger KITLG p53-RE, harbor the greater
testicular cancer risk. This finding supports the intriguing hypoth-
esis that p53-regulated paracrine growth factor signaling may be
associated with promoting tumor development. Indeed, acti-
vating mutations of the KIT receptor have been shown to pro-
mote tumor formation and the receptor is currently targeted by
many therapeutic agents in cancer treatments. In testicular can-
cer, the KIT pathway is central to its molecular pathology (Gilbert
et al., 2011), and many components of this pathway are somat-
ically mutated to activate KIT signaling. Moreover, the six SNPs
identified in testicular cancer GWASs to associate with differen-
tial cancer risk reside in three genes in this pathway: KITLG,
SPRY4, and BAK1. Although p53 is themost commonly mutated
gene in human cancer, whereby 50% of all cancers have mutant
p53, less than 3% of testicular cancers do (Lutzker, 1998; Peng
et al., 1993). In many cancers that retain wild-type p53 genes, the
cells have frequently attenuated p53 through other mechanisms
such as the overexpression of direct inhibitors, like the amp-
lification of the MDM2 oncogene. In dramatic contrast to these
observations, p53 signaling is often found to be robust in human
testicular cancers (Chresta et al., 1996; Gutekunst et al., 2011;
Lutzker and Levine, 1996). Intriguingly, 80% of testicular germ
cell tumors can be cured with DNA-damaging therapies, and
the retention of p53 activity has been implicated in this
astounding cure rate through chemotherapeutics (Bosl andMot-
zer, 1997; Gutekunst et al., 2011; Houldsworth et al., 1998; Mas-
ters and Ko¨berle, 2003). Together with the data presented in this
report, these observations suggest that the G allele of KITLG
p53-RE allows increased p53-dependent upregulation of KITLG
expression, which drives male germ cell proliferation rather than
arrest in the presence of DNA damage, thus promoting tumori-
genesis and thereby offering an explanation for the abnormal
retention of p53 activity in testicular tumors.
Testicular cancer has been demonstrated to harbor a strong
genetic component to its development (Czene et al., 2002). A
very interesting observation in support of this is the fact that
testicular cancer is 4- to 5-fold more prevalent in Caucasians
compared to African populations (Garner et al., 2005; Holmes
et al., 2008; Moul et al., 1994; Ross et al., 1979). Additional
studies have gone on to provide further evidence, demonstrating
that African American males have maintained the lower risk for
testicular cancer over several generations, while acquiring higher
risk of other cancers, such as colorectal (Chia et al., 2010; Ross
et al., 1979). Here, we have shown that the G allele, which in-
creases the affinity for p53 and associates with greater testicular
cancer risk, is significantly more frequent in Caucasians than in
Africans. Furthermore, among Caucasians, the G allele is
harbored in a haplotype structure that suggests that it has under-
gone a selective sweep (Lao et al., 2007). It is fascinating that the
G allele has arisen to such prevalence in Caucasians, wherepigmentary system function is reduced compared to Africans.
In the skin, KIT signaling serves to increase melanin production
and melanocyte migration in its key role in mediating the UV pro-
tective tanning response. Interestingly, in Caucasians, variation
in all other pigmentation genes that we know about results in
impaired melanogenic function and concomitant reduced
pigmentation. Thus, it is intriguing to hypothesize that theG allele
(and its linked alleles) may have risen to such a high frequency in
Caucasians to benefit UV protection in lighter-skin individuals.
Although we have provided evidence that the KITLG p53-SNP
and its haplotype show signs of positive selection, when we
looked at polymorphic p53 enhancers genome-wide, we
observed significant signs of negative selection. Specifically,
we demonstrated that the frequency of polymorphic p53-REs
was significantly lower in the genomic regions occupied by
p53, compared to p53-REs, for which p53 occupancy was not
observable (Figure 7C). This suggests that SNPs in active p53-
binding sites could have been under negative or purifying selec-
tion throughout evolution. During the past three decades of
intense research, the regulation of the p53 pathway has been
clearly shown to be under tight control, which is appropriate
for a signaling pathway making cellular life or death decisions
(Lu, 2010). Indeed, small changes in levels of target genes
have been well documented to measurably change the p53
stress response, resulting in aberrant cellular fate decisions. As
mentioned above, the p53 stress response has been shown
not only to be important in tumor suppression, but also in
many key physiological processes that could have been sub-
jected to selection pressure throughout human evolution (Belyi
et al., 2010; Junttila and Evan, 2009; Lu et al., 2009). Together,
these observations suggest the possibility that mutations in
p53-REs are primarily detrimental but that in rare instances,
they impart selective benefits.
EXPERIMENTAL PROCEDURES
Searching for Putative p53-REs Using the PWM
We constructed a position weight matrix (PWM) for p53-REs based on 228
functional p53-RE sequences from the literature (NCBI PUBMED database)
that were discovered by experimental methods investigating DNA-protein
interaction, including electrophoretic mobility shift assay, DNase I footprinting,
and promoter reporter gene constructs. Once a PWM model has been
compiled, the PWM score for any putative p53-RE is calculated by summing
the individual matrix values that correspond to the observed nucleotide at
each position in that site. The potential p53-REs in a genomic sequence
were detected by sliding a window along the input sequence, similar to the
method we used to detect the antioxidant response elements but with an
added feature that considers the spacer in p53-REs (Wang et al., 2007).
ChIP-Seq Data Analysis
The p53 ChIP-seq data are combined from three published studies and our
unpublished data (M.R.C., D.S., X.W., D.A.B.). For the three published studies,
the raw reads were downloaded fromNCBI SRA database. All sequence reads
generated from Illumina Genome Analyzer II were aligned against human refer-
ence sequence (GRCh37p5, or hg19, June 2011) using Burrows-Wheeler
Alignment (BWA) Tool (Li et al., 2008).
Allele Specific Expression and Allele Specific Binding Using Real-
Time PCR
The mean Ct values for each dye were calculated from the three technical rep-
licates. Standard curves for both dyes (FAM and VIC) were constructed usingCell 155, 410–422, October 10, 2013 ª2013 Elsevier Inc. 419
serial dilutions of genomic DNA, or input DNA in the case of ChIP material. The
mean Ct values were plotted against the preamplification DNA concentrations
and a logarithmic regression was performed. Calculating an independent log-
arithmic regression for each of the dyes allowed us to quantify the fold differ-
ence in fluorescence between the alleles.
Transfection and Luciferase Assays
All transfections were done in triplicate. Forty hours posttransfection the
cells were assayed. Measurements of firefly luciferase activity were normal-
ized by Renilla luciferase activity for transfection efficiency. Mean values
and standard deviations of the triplicates were calculated. When the
Luciferase reporter vector was cotransfected with an expression vector
(pcDNA3) containing wild-type p53 cDNA Luciferace/Renilla ratios of the
cells cotransfected with the wild-type p53 were normalized to that of the
Luciferace/Renilla ratios of the cells cotransfected with the empty pcDNA3
vector.
Embryonic Stem Cell Enhancer Assays
A 452 bp region of genomic KITLG, containing either the A or G alleles, was
amplified by PCR and cloned upstream of an expression construct consisting
of the minimal Hsp68 promoter (Hspa1b) driving the expression of a beta-
galactosidase gene (LacZ). These two experimental constructs, together
with the empty Hsp68-LacZ control construct, were cloned into PhiC31 inte-
grase-mediated cassette exchange shuttle vector, pCB92 (Chen et al., 2011)
downstream of a murine H19 insulator. ES cell clones haboring the
enhancer-promoter-LacZ constructs at the ROSA26 locus were generated
by PhiC31 integrase-mediated cassette exchange into IDG26.10-3 ES cell
line as described (Hitz et al., 2007). Experiments were repeated at least three
times on separate days using 5–7 technical replicates on each occasion.
Natural Selection Analysis
The integrated haplotype scores were estimated using the package ‘‘re-
hh’’(Gautier and Vitalis, 2012), following the method described by Voight
et al. (2006). Haplotype data for the CEU population were downloaded from
the 1000 Genomes (phase 1 data) (Abecasis et al., 2012). To calculate the
scores, only SNPs with a MAF larger than 0.05 were used. The normalization
of the scores was performed with a 0.05 allele frequency window.
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The GEO accession number for the p53 ChIP-seq data from human lympho-
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